NewLimit receives $40 Million Series A for cellular reprogramming
NewLimit is a company that uses epigenetic reprogramming to extend the human life expectancy. Dimension, Founders Fund and Kleiner Perkins are among prominent investors who have invested $40 million.
The company believes that epigenetic reprogramming can help to find therapies for aging. NewLimit believes that its innovative approach will also be able to address age-related diseases. They aim to revolutionize aging biology, and pave way for transformational advancements in healthcare.
Longevity. Technology: Epigenetic Reprogramming is a new but exciting area of geroscience. This involves identifying specific transcription factors which can alter gene expression or cell behavior. It is a way to reverse or modify the epigenetic markers that are associated with aging. This approach provides a unique chance to rejuvenate tissues and cells, possibly slowing or even reversing aging and related diseases. NewLimit claims that its products were designed to treat the aging process, but also believe \”these products can treat or prevent many diseases related to aging such as fibrosis and infectious disease.\”
Source:
NewLimit secures $40 million Series A to accelerate cellular reprogramming
